Study published in ‘American Journal of Respiratory Cell and Molecular Biology’ validates Qureight’s deep-learning models and imaging platform beyond fibrotic lung disease, into new therapeutic areas for severe respiratory disease. Data demonstrate sensitive quantification of vascular remodelling and prediction of disease severity from routine CT scans, following surgical removal of chronic blood clots. Automated insights from application of Vascul8 model enabled identification of patients at high risk of residual pulmonary hypertension post-surgery which will reduce the need for routine post-operative right heart catheterisation.

The 2025 European Respiratory Society Congress takes place 27 September-1 October in Amsterdam, NL. Qureight’s strong presence at the event reflects the Company’s mission to advance the understanding of lung and heart disease through its AI-powered data and imaging curation platform, enabling Qureight to build products that accelerate clinical trials, identify new endpoints, and help to bring new treatments to patients faster.

Qureight appoints Professor Tamera Corte to their Scientific Advisory Committee.

Appointment underscores Qureight’s commitment to drive adoption of its AI-powered imaging and clinical data curation platform to support clinical trials and accelerate drug development timelines for lung and heart diseases. Former big tech executive and NVIDIA director with proven track record of driving innovation in adoption of AI in life sciences and healthcare

Qureight’s advanced AI 3D imaging platform to be used across clinical trial to evaluate anatomical lung changes in adult patients, including during patient enrolment. CAL101 is a first-in-class monoclonal antibody that neutralises the S100A4 protein, which is an upstream driver and amplifier of the multiple pro-fibrotic pathways active in IPF.

Qureight’s deep-learning image biomarkers and clinical data analytics platform used to analyse enrolled idiopathic pulmonary fibrosis (IPF) patient data, supporting efficacyoutcome and expansion to larger global patient studies.

Qureight, a deep-learning analytics company accelerating drug development through AI-powered data curation, today announced that its digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research.

Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial

The collaboration will integrate Qureight’s deep-learning platform into Rein’s planned Phase 2 trial of its lead asset LTI-03, for the treatment of IPF.

Qureight will have a major presence at the upcoming American Thoracic Society (ATS) 2025 International Conference, taking place from 18–21 May in San Francisco

Qureight are thrilled to welcome Dr. Paul Ford MD, PhD to their Scientific Advisory Committee!

Qureight Ltd, a Core Imaging Platform based in Cambridge UK, today announced changes to the company’s Board of Directors.

Qureight and Remedy Cell have partnered to validate RC-0315’s mechanism of action in idiopathic pulmonary fibrosis (IPF)

Qureight has appointed Patrick Driscoll as the company’s Chief Financial Officer, strengthening the company’s financial and operational capabilities.

As we step into 2025, we take a moment to reflect on the past few months, which has been a busy and exciting period for Qureight. With new team members, Christmas parties, securing funding, industry recognition, and new partnerships, we’re making progress in our mission to transform clinical trials through deep-learning imaging.

Qureight Ltd and Vicore Pharma today announce the implementation of Qureight’s Core Imaging Platform within the global Phase 2b ASPIRE trial investigating buloxibutid in patients with idiopathic pulmonary fibrosis (IPF).

The partnership will commence with the ongoing MIST study, a Phase 2b clinical trial evaluating the safety and efficacy of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis (PPF).

This milestone highlights our commitment to safeguarding sensitive data and establishing greater trust within our partners and stakeholder community.

‍Techbio company Qureight has appointed Dr Simon Walsh to the role of Chief Scientific Officer (CSO). This significant strategic appointment will deliver expert clinical oversight and technical support to drive Qureight's research and development pipeline.

Qureight has announced a partnership with King Faisal Specialist Hospital and Research Centre for Innovative Lung Transplant Research Pilot

Qureight has announced the appointment of Javier Alvarez Valle to the Qureight Scientific Advisory Board.

Qureight has announced the appointment of Claus Torp Jensen to the role of Chairperson of the Board.

Qureight and Vicore Pharma publish results indicating that patients with earlier stage idiopathic pulmonary fibrosis (IPF) are more likely to have improvement in lung function in response to treatment with Vicore’s novel angiotensin II type 2 agonist, C21.

Cambridge-based data analytics company Qureight has entered into a multi-year collaboration with the biopharmaceutical company AstraZeneca.

The Qureight team is delighted to welcome Dr Pilar Rivera-Ortega on to our Scientific Advisory Board for Idiopathic Pulmonary Fibrosis (IPF).

Qureight is excited to be collaborating with the patientMpower team on a project to uncover new prognostic markers in interstitial lung disease (ILD).

Dr Muhunthan Thillai CEO said "We are really excited that Dr Fernandez has joined us to assist the company with our data strategy as we expand operations. Xose brings over 25 years’ experience...

Qureight has met the requirements to use our quality management system for the design of medical devices. We are pleased as it shows our dedication to maintaining a high quality QMS as we continue to develop our platform.